bromodeoxyuridine has been researched along with Hypopharyngeal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, M; Eicheler, W; Krause, M; Menegakis, A; Thames, HD; Yaromina, A | 1 |
| Attal, P; Bobin, S; Bosq, J; Bourhis, J; Dendale, R; Eschwege, F; Fortin, A; Hill, C; Janot, F; Luboinski, B; Malaise, EP; Marandas, P; Schwaab, G; Wibault, P; Wilson, G | 1 |
2 other study(ies) available for bromodeoxyuridine and Hypopharyngeal Neoplasms
| Article | Year |
|---|---|
Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours.
Topics: Aged; Aged, 80 and over; Animals; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Breaks, Double-Stranded; Female; Histones; Humans; Hypopharyngeal Neoplasms; Male; Mice; Radiation Tolerance | 2011 |
Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks.
Topics: Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Division; Disease-Free Survival; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Multivariate Analysis; Neoplasm Staging; Oropharyngeal Neoplasms; Prospective Studies; Radiotherapy Dosage; Time Factors; Treatment Failure | 1996 |